Medicine Supply Notification: Rasagiline 1mg tablets

Department of Health and Social Care (DHSC) has issued a medicine supply notification for Rasagiline 1mg tablets.


Tier 3 – high impact

Date of issue 16th November 2023

  • Rasagiline 1mg tablets are in limited supply until mid-December 2023.
  • Unlicensed supplies of rasagiline 1mg tablets may be sourced, lead times vary.
  • Selegiline (Eldepryl®) 5mg and 10mg tablets remain available and can support increased demand.
  • Safinamide (Xadago®) 50mg and 100mg tablets remain available and can support increased demand.

Unlicensed products

The following specialist importer(s) have confirmed they can source unlicensed rasagiline 1mg tablets (please note there may be other companies that can also source supplies):

If there is currently no listing on dm+d for the imported product for prescribers to select using their prescribing systems an EPS prescription for the unlicensed product cannot be issued. Where a prescriber wishes to prescribe a specially manufactured or imported product, an FP10 paper prescription should be issued as ‘Rasagiline 1mg tablets. (Special Order)’ and endorsed by the pharmacy as a non-Part VIIIB special with the following information:

  • Amount dispensed over pack size used;
  • Invoice price per pack size from which the order was supplied less any discount or rebate;
  • Manufacturers’/importers’ MHRA licence number;
  • Batch number of the product supplied;
  • SP

A copy of this medicine supply notification, including further information, has been sent to all pharmacy NHS email addresses.

DHSC and NHSE/I have now launched an online Medicines Supply Tool, which provides up to date information about medicine supply issues. The contents of these MSNs can now be viewed on the Tool.

The Tool also details any changes to resupply dates and updates to the entries.

To access the Tool you will need  an NHS email address. Once set up and logged in, you will be able to access it online.

New shortages not listed on the SPS website, can be reported using our shortage reporting tool.